欧洲创伤性脑损伤患者高强度治疗的使用与影响:CENTER-TBI分析
该研究基于CENTER-TBI队列,分析欧洲52个ICU中758例接受颅内压监测的创伤性脑损伤患者,41%(313例)接受至少一种高强度治疗(代谢抑制、低温<35°C、强化过度通气PaCO2<4 kPa、去骨瓣减压),中心间使用差异显著(中位OR 2.26)。倾向性评分匹配285对显示高强度治疗与6个月不良结局无显著关联(OR 1.4,95%CI 1.0-2.0),但排除第1天高强度治疗或任何一天代谢抑制的敏感性分析显示与更差结局显著相关。作者认为第1天后高强度治疗与更差结局的关联可能反映积极使用、未测量混杂或不恰当的升级策略,需进一步研究。
要点
- 在CENTER-TBI的758例颅内压监测TBI患者中,41%(313例)接受至少一种高强度治疗,中心间使用差异显著(中位OR 2.26)。
- 高强度治疗常未从低级别治疗阶梯升级而短暂使用;接受高强度治疗者中38%获得良好结局(GOSE≥5)。
- 倾向性评分匹配285对显示高强度治疗与6个月不良结局无显著关联(OR 1.4,95%CI 1.0-2.0)。
- 敏感性分析排除第1天高强度治疗或任何一天代谢抑制后,高强度治疗与更差结局显著相关。
- 作者认为第1天后高强度治疗与更差结局的关联可能反映积极使用、未测量混杂或不恰当升级策略。
适用人群与场景
- 纳入CENTER-TBI研究中ICU层接受颅内压监测的创伤性脑损伤患者。
- 研究场景为欧洲52个重症监护病房。
诊断标准与关键阈值
- 高强度治疗水平(TIL)包括:代谢抑制、低温(<35°C)、强化过度通气(PaCO2<4 kPa)、继发性去骨瓣减压。
- 结局评估采用6个月格拉斯哥结局扩展评分(GOSE),良好结局定义为GOSE≥5。
红旗征与不能漏的情况
- 影像学上存在脑疝征象。
研究设计与关键结果
- 研究类型为CENTER-TBI队列分析,纳入758例接受颅内压监测的创伤性脑损伤患者,来自欧洲52个中心。
- 313例(41%)接受至少一种高强度治疗,中心间使用差异显著(中位OR 2.26)。
- 患者常短暂接受高强度治疗,且未从低级别治疗升级。
- 接受高强度治疗的患者中38%获得良好结局(GOSE≥5)。
- 倾向性评分匹配285对显示高强度治疗与更差结局无显著关联(OR 1.4,95%CI 1.0-2.0)。
- 敏感性分析排除第1天高强度治疗或任何一天代谢抑制后,显示与更差结局显著相关。
证据类型、等级与局限
- 证据类型:基于CENTER-TBI队列的观察性分析,采用随机效应逻辑回归和倾向性评分匹配。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为第1天后高强度治疗与更差结局的关联可能反映积极使用、未测量混杂或不恰当的升级策略。
- 作者指出需要进一步研究高强度治疗的影响。
指南或共识出处
- CENTER-TBI研究,核心研究注册于ClinicalTrials.gov,编号NCT02210221,注册日期2014年6月8日;Resource Identification Portal(RRID: SCR_015582)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To study variation in, and clinical impact of high Therapy Intensity Level (TIL) treatments for elevated intracranial pressure (ICP) in patients with traumatic brain injury (TBI) across European Intensive Care Units (ICUs).
METHODS: We studied high TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation (PaCO2 < 4 kPa), and secondary decompressive craniectomy) in patients receiving ICP monitoring in the ICU stratum of the CENTER-TBI study. A random effect logistic regression model was used to determine between-centre variation in their use. A propensity score-matched model was used to study the impact on outcome (6-months Glasgow Outcome Score-extended (GOSE)), whilst adjusting for case-mix severity, signs of brain herniation on imaging, and ICP.
RESULTS: 313 of 758 patients from 52 European centres (41%) received at least one high TIL treatment with significant variation between centres (median odds ratio = 2.26). Patients often transiently received high TIL therapies without escalation from lower tier treatments. 38% of patients with high TIL treatment had favourable outcomes (GOSE ≥ 5). The use of high TIL treatment was not significantly associated with worse outcome (285 matched pairs, OR 1.4, 95% CI [1.0-2.0]). However, a sensitivity analysis excluding high TIL treatments at day 1 or use of metabolic suppression at any day did reveal a statistically significant association with worse outcome.
CONCLUSION: Substantial between-centre variation in use of high TIL treatments for TBI was found and treatment escalation to higher TIL treatments were often not preceded by more conventional lower TIL treatments. The significant association between high TIL treatments after day 1 and worse outcomes may reflect aggressive use or unmeasured confounders or inappropriate escalation strategies.
TAKE HOME MESSAGE: Substantial variation was found in the use of highly intensive ICP-lowering treatments across European ICUs and a stepwise escalation strategy from lower to higher intensity level therapy is often lacking. Further research is necessary to study the impact of high therapy intensity treatments.
TRIAL REGISTRATION: The core study was registered with ClinicalTrials.gov, number NCT02210221, registered 08/06/2014, https://clinicaltrials.gov/ct2/show/NCT02210221?id=NCT02210221&draw=1&rank=1 and with Resource Identification Portal (RRID: SCR_015582).
参考来源
- Huijben JA, Dixit A, Stocchetti N, et al. Use and impact of high intensity treatments in patients with traumatic brain injury across Europe: a CENTER-TBI analysis. Crit Care. 2021. PMID: 33622371. doi:10.1186/s13054-020-03370-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。